CN103405574B - Medicinal composition for treating hypertension - Google Patents
Medicinal composition for treating hypertension Download PDFInfo
- Publication number
- CN103405574B CN103405574B CN201310325756.9A CN201310325756A CN103405574B CN 103405574 B CN103405574 B CN 103405574B CN 201310325756 A CN201310325756 A CN 201310325756A CN 103405574 B CN103405574 B CN 103405574B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- radix
- present
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 48
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims description 25
- 230000001631 hypertensive effect Effects 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000002566 Capsicum Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 239000006002 Pepper Substances 0.000 abstract 1
- 235000016761 Piper aduncum Nutrition 0.000 abstract 1
- 235000017804 Piper guineense Nutrition 0.000 abstract 1
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 235000008184 Piper nigrum Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000000582 semen Anatomy 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000628997 Flos Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Abstract
The invention discloses a medicinal composition for treating hypertension, and relates to the technical field of the traditional Chinese medicine. The medicinal composition is prepared from six kinds of pure natural traditional Chinese medicine comprising pepper, selfheal, trichosanthes kirilowii maxim, radix ophiopogonis, barbary wolfberry fruit and liquorice according to a certain weight ratio. The medicinal composition for treating the hypertension is simple in composition, convenient to take and simple in preparation technology, and also has the advantages of less dosage, high curing rate, low irritation, no toxic and side effects, available raw materials, no critical shortage, low price and the like.
Description
Technical field
The present invention relates to technical field of Chinese medicine, be specifically related to one and treat hypertensive pharmaceutical composition and preparation method thereof.
Background technology
Hypertension a kind ofly continues to raise as the chronic disease of main manifestations with arteriotony, often causes the pathological changes of the vitals such as the heart, brain, kidney and occur corresponding consequence.Long-term hypertension can cause cardiovascular disease as myocardial infarction, coronary heart disease etc., can also cause renal arteriosclerosis, thus cause renal insufficiency, uremia etc.Therefore improve the understanding to hypertension, have extremely important meaning to early prevention, in time treatment.
Doctor trained in Western medicine thinks that hypertension is a kind of disease that can not be cured, and can only maintain the stable of blood pressure by enalapril meleate.But practical situation is the prolongation along with the time, and the state of an illness increases the weight of gradually, serious meeting causes the diseases such as patient's cerebral hemorrhage, cerebral embolism, hemiplegia.
Chinese invention patent CN200710015375.5 discloses a kind of Chinese medicinal capsule for the treatment of person in middle and old age's essential hypertension, is, Herba Asari formulated Chinese medicinal capsule each by the Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Polygoni Multiflori, Fructus Mori, Fructus Ligustri Lucidi, Semen Astragali Complanati, Fructus Tribuli, Herba Cynomorii, Radix Achyranthis Bidentatae, Semen Cuscutae, Semen Raphani, Rhizoma Atractylodis Macrocephalae (parched), Fructus Lycii, Semen Plantaginis, Semen Cassiae, Flos Chrysanthemi, Radix Polygalae, Rhizoma Acori Graminei.
Chinese invention patent CN200610165007.4 discloses one and treats hypertensive Chinese medicine oral liquid, and it is made for raw material with Semen Persicae, Radix Platycodonis, Concha Haliotidis, Flos Carthami, Radix Bupleuri, Fructus Gardeniae, Radix Angelicae Sinensis, Fructus Aurantii, Poria cum Radix Pini, Radix Rehmanniae, Radix Glycyrrhizae, Radix Scutellariae, Rhizoma Chuanxiong, Rhizoma Gastrodiae, the Cortex Eucommiae, Radix Paeoniae Rubra, Ramulus Uncariae Cum Uncis, Herba Leonuri, Radix Cyathulae, Semen Cassiae, Herba Taxilli, Caulis Polygoni Multiflori.
Chinese invention patent CN201010187963.9 discloses one and treats hypertensive Chinese medicine, by weight, formulated by following component: Ramulus Uncariae Cum Uncis 20 parts, Concha Haliotidis 20 parts, the Cortex Eucommiae 15 parts, Radix Puerariae 15 parts, Semen Cassiae 20 parts, Cortex Moutan 15 parts, Radix Scutellariae 10 parts, Cortex Lycii 10 parts, the Radix Paeoniae Alba 15 parts, Radix Bupleuri 15 parts, 10 parts, Rhizoma Gastrodiae, Radix Achyranthis Bidentatae 15 parts, Herba Taxilli 15 parts, Pheretima 15 parts, Herba Leonuri 15 parts, Caulis Polygoni Multiflori 15 parts.
The hypertensive Chinese medicine product of existing treatment, taste of Chinese medicine number used is too much, has relatively reduced the medicine proportion of therapeutical effect, have impact on pharmic function to play, the course for the treatment of is long, and effect is undesirable, and mostly be decoction or pill, comparatively difficulty taken by Western medicine, also have impact on the popularization of Chinese medicine widely.
Summary of the invention
The object of the present invention is to provide a kind of short treating period, instant effect, be applicable to the hypertensive Chinese medicine compositions of oral, safe and reliable, that price is low treatment.
In order to realize object of the present invention, the present invention provides one through research for many years and treats hypertensive Chinese medicine composition and it is characterized in that being made up of following raw material on the basis of ancestral side: Pericarpium Zanthoxyli, Semen Cassiae, Fructus Crataegi, Radix Angelicae Sinensis, Spica Prunellae, Fructus Lycii, Fructus Trichosanthis, Rhizoma Coptidis.Particularly, be made up of the raw material of following weight portion:
Pericarpium Zanthoxyli 6-10 part, Spica Prunellae 8-24 part, Fructus Trichosanthis 6-10 part, Radix Ophiopogonis 2-5 part, Fructus Lycii 8-14 part, Radix Glycyrrhizae 6-10 part.
Preferably, Chinese medicine composition of the present invention is made up of the raw material of following weight portion:
6 parts, Pericarpium Zanthoxyli, Spica Prunellae 18 parts, Fructus Trichosanthis 8 parts, Radix Ophiopogonis 3 parts, Fructus Lycii 10 parts, 6 parts, Radix Glycyrrhizae.
Much Chinese medicine all has the effect reduced blood pressure, and the traditional Chinese medical science thinks that blood pressure lowering not only needs the rubbish impurity in dredging vascellum, cleaning blood, also needs to repair the impaired vital organs of the human body.Chinese medicine composition energy conditioning viscera function of the present invention, recovers equilibrium between yin and yang, can treating the liver deficiency of the kidney yin or excessive rising of liver-YANG, control is cloudy damage in front yang hyperactivity in after deficiency of both YIN and YANG.Can Coryza Treated by Syndrome Differentiation internal organs imbalance between YIN and YANG, raw in wind-fire, expectorant becomes silted up and hands over resistance, the inverse symptom such as disorderly of QI and blood, and the outward manifestation symptom such as the headache caused by above-mentioned symptom, dizzy, tinnitus, spirit is unable.
Pericarpium Zanthoxyli: acrid in the mouth, warm in nature.Slightly poisonous.Return spleen, stomach, kidney channel.Can salivation be promoted, increase appetite; The effect distended the blood vessels.Spica Prunellae: bitter, acrid, cold.Control conjunctival congestion and swelling pain, headache.Clearing away liver-fire, control hypertension, hyperlipidemia, high blood viscosity and hyperglycemia.Radix Ophiopogonis: have another name called dwarf lilyturf, book band grass, Radix Ophiopogonis, nature,taste and action: sweet, micro-hardship, cool, Yin-nourishing and body fluid promoting, nourishing the lung to arrest cough, clear away heart-fire relieving restlessness.Control consumption of body fluid caused by febrile disease, vexed, thirsty, dry pharynx lung-heat, cough, pulmonary tuberculosis, haematemesis, spitting of blood, lung abscess.Fructus Lycii: sweet in the mouth; The flat nourishing the liver of property; Nourishing kidney; Lung moistening.There is enhancing human body immunity function, Tumor suppression, blood sugar lowering, blood fat reducing, the functions such as resisting fatigue.Fructus Trichosanthis: sweet, micro-hardship, cold.GUIXIN, lung, liver, stomach, large intestine channel.Clearing away heat and eliminating phlegm, relieving stuffiness of the chest by dispersing aggregation of pathogens, moisturizes laxation.For cough due to lung-heat, the turbid Huang of expectorant is thick, obstruction of qi in the chest and cardialgia.Radix Glycyrrhizae: sweet in the mouth, property is put down, nontoxic.Treating disorders in five ZANG-organs six internal organs cold and heat pathogen, hard muscles and bones, longue meat, times strength, removing toxic substances, clothes are made light of one's life by commiting suicide and are prolonged life for a long time.Raw by pathogenic fire purging heat, ripe use is fallen apart exterior cold, goes pharyngalgia, except pathogenic heat, and slow healthy energy, yin nourishing blood, tonifying the spleen and stomach, lung moistening.All medicine 5 use, can balance internal organs negative and positive, clearing away liver-fire, Disperse hepatic depression, blood vessel dilating, blood fat-reducing blood pressure-decreasing above.
For solving the problems of the technologies described above, the present invention also provides a kind of dosage form for the treatment of hypertensive Chinese medicine preparation.Above-mentioned Chinese medicine composition of the present invention adds various customary adjuvant required when preparing different dosage form, such as disintegrating agent, lubricant, adhesive etc. are prepared into the conventional oral formulations of any one with the method for Chinese medicinal of routine, can be such as tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, honey pill agent, powder, sublimed preparation, solution or plaster etc.
Chinese medicine composition of the present invention is preferably capsule, and concrete preparation method is as follows: the Pericarpium Zanthoxyli taken according to weight proportion of the present invention, Spica Prunellae, Fructus Trichosanthis, Radix Ophiopogonis, Fructus Lycii, Radix Glycyrrhizae, clean, and dries; By above-mentioned pulverizing medicinal materials, cross 80-120 mesh sieve, after sterilizing, insert capsule, every content of dispersion 0.4 gram.
Usage and dosage: dosage of the present invention depends on concrete dosage form, the factors such as patient age, body weight, health status.Capsule of the present invention is every day 2 times, and can be kept to according to the state of an illness after the course for the treatment of and take medicine every day 1 time, each serving 2 ~ 4, warm water takes.30 days courses for the treatment of.
The present invention treats hypertensive Chinese medicine composition and has a little following compared with Chinese medicine composition: flavour of a drug first of the present invention are simplified, prescription is simple: the present invention treats hypertensive Chinese medicine composition and is only made up of 6 taste Chinese medicines, compared with the prescription of existing Chinese medicine compound tens of taste medical material easily, greatly reduce medication flavour of a drug, reduce the uncertainty of prescription simultaneously.Secondly the present invention is mouth preparation capsule, taking convenience, preparation process is simple: the present invention treats hypertensive Chinese medicinal composition capsules agent and takes convenient compared with the decoction in existing traditional Chinese medicine technology, and preparation method only needs crushed filling capsule, water extraction alcohol extraction process that need not be complicated.In addition also to have medication few in the present invention, and cure rate is high, and zest is little, has no side effect, raw material is easy to get, medication without in great shortage, the advantage such as cheap.
Detailed description of the invention
Below by way of concrete enforcement embodiment, the invention will be further described, but should be appreciated that this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Embodiment 1
Weighting raw materials material Pericarpium Zanthoxyli 6g, Spica Prunellae 8g, Fructus Trichosanthis 6g, Radix Ophiopogonis 2g, Fructus Lycii 8g, Radix Glycyrrhizae 6g clean, dry, and pulverizes, and crosses 120 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Embodiment 2
Weighting raw materials material Pericarpium Zanthoxyli 6g, Spica Prunellae 18g, Fructus Trichosanthis 8g, Radix Ophiopogonis 3g, Fructus Lycii 10g, Radix Glycyrrhizae 6g.Clean, dry, pulverize, cross 120 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Embodiment 3
Weighting raw materials material Pericarpium Zanthoxyli 6g, Spica Prunellae 18g, Fructus Trichosanthis 8g, Radix Ophiopogonis 3g, Fructus Lycii 10g, Radix Glycyrrhizae 6g.Clean, dry, pulverize, cross 120 mesh sieves, add binding agent, disintegrating agent, namely tabletting obtains tablet of the present invention.
Embodiment 4
Weighting raw materials material Pericarpium Zanthoxyli 10g, Spica Prunellae 24g, Fructus Trichosanthis 10g, Radix Ophiopogonis 5g, Fructus Lycii 14g, Radix Glycyrrhizae 10g.Clean, dry, pulverize, cross 80 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Pericarpium Zanthoxyli 6-10 part, Spica Prunellae 8-24 part, Fructus Trichosanthis 6-10 part, Radix Ophiopogonis 2-5 part, Fructus Lycii 8-14 part, Radix Glycyrrhizae 6-10 part.
Embodiment 5
Weighting raw materials material Pericarpium Zanthoxyli 7g, Spica Prunellae 16g, Fructus Trichosanthis 8g, Radix Ophiopogonis 3g, Fructus Lycii 8g, Radix Glycyrrhizae 8g.Clean, dry, pulverize, cross 80 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Embodiment 6
Weighting raw materials material Pericarpium Zanthoxyli 6g, Spica Prunellae 24g, Fructus Trichosanthis 8g, Radix Ophiopogonis 5g, Fructus Lycii 8g, Radix Glycyrrhizae 6g.Clean, dry, pulverize, cross 80 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Embodiment 7
Weighting raw materials material Pericarpium Zanthoxyli 10g, Spica Prunellae 12g, Fructus Trichosanthis 8g, Radix Ophiopogonis 3g, Fructus Lycii 14g, Radix Glycyrrhizae 10g.Clean, dry, pulverize, cross 80 mesh sieves, then insert No. 0 capsule, every dress 0.4g, obtains capsule of the present invention.
Toxicology test:
Test example 1: acute toxicity test of the present invention
One, test material:
Animal: Kunming mouse, body weight 21-24g, male and female half and half, Shandong University's biology laboratory breeding.Medicine: the embodiment of the present invention 2 capsule;
Two, method:
1, LD50 calculates: adopt improvement karber's method, mice is divided into 5 groups at random, often organize 10, male and female half and half, dissolve embodiment 2 capsule adding distil water, are made into Cmax, by the administration of mice maximum permission capacity, institute is followed successively by 18,14.4 to dosage by crude drug amount, 11.5,9.2,7.4 (g.kg-1), in animal fasting (can't help water) after 18 hours, administration at twice in one day (interval half an hour), each 0.5ml, observes animal dead situation.
2, maximum tolerated dose measures (MTD value): get mice 20, each 10 of male and female.Tablet adding distil water is dissolved, is made into maximum concentration, by the maximum tolerated dose of animal, feed device and can twitch to inject to fill with and be as the criterion.In animal fasting (can't help water) after 18 hours, administration at twice in one day (interval half an hour), each 0.5ml (every ml containing crude drug 0.36g), total dose is 18g crude drug/kg.d, 300 times of quite clinical adult 50Kg body weight consumption.Continuous Observation 7 days after administration.
Three, result of the test:
In LD50 calculates when giving mice with maximum acceptable concentration and maximum permission capacity (18g/Kg.d), have no dead mouse, namely LD50 is not measured, ask maximum tolerated dose only, in 7 day observation period, its appetite of animal, activity, hair color, the mental status etc. are all normal, grow normal, there are no death.Namely select the 300 times of doses being equivalent to clinical dosage, and have no adverse reaction, show that acute toxicity is minimum, MTD > 18g/Kg.d.
Experimental example 2: long term toxicity test
Medicine: the embodiment of the present invention 2 prescription.
Animal: regular grade SD rat 24, body weight 200g ± 10g, male and female half and half, are divided into 3 groups at random.
Method and result:
1) Pharmaceutical formulations: point high, medium and low three dosage groups, are respectively 300,150,75 times of clinical application amount, mixes with the normal saline 1: 1 containing 2% Radix Acaciae senegalis;
2) experiment adopts gastric infusion mode, successive administration 45d, namely more than 3 clinical cycles, observe animal general toxic reaction and the order of severity, each position is checked by rule of operation after execution, and carry out hematology, the pathological examination of the main organs such as ALT, BUN and the heart, liver, spleen, lung, kidney, stomach;
3) long-term oral administration, there is not toxic reaction in high, medium and low three dosage treated animals.Physically well develop.Macroscopic appearance and main organs no abnormality seen.Peripheral hemogram and Serum ALT, BUN compare with matched group and change without pathologic.The all not significant changes such as the pathological replacement heart, liver, spleen, lung, kidney, stomach, to think through proved by pathology to animal without poisoning manifestations.
For investigating clinical efficacy and the safety of medicine of the present invention further, hyperpietic is selected to carry out clinical observation to the curative effect of medicine of the present invention.
Test case standard: 1) include case standard in: determine according to the new Treatment Guidelines for Hypertension that World Health Organization (WHO)/International Society of Hypertension (WHO/ISH) promulgates, namely do not taking under antihypertensive drugs, systolic pressure >=18.7kPa (140mmHg) and (or) diastolic pressure >=12.0kPa (90mmHg), after pressure measurement first finds that blood pressure raises, should at least measure twice different occasion to determine whether blood pressure raises.2) Excluded cases standard: A age below 18 one full year of life or more than 70 one full year of life, trimester of pregnancy or women breast-feeding their children, those who are allergic to this drug; B is associated with the severe primary diseases such as liver, kidney and hemopoietic system, psychotic; C is all does not meet inclusive criteria, not by regulation medication, cannot judge that curative effect or data are not congruent and affect the treatment or safety judgement person.
Criterion of therapeutical effect: cure as systolic pressure≤18.7kPa (140mmHg) and diastolic pressure≤12.0kPa (90mmHg).Be effectively systolic pressure >=18.7kPa (140mmHg) and (or) diastolic pressure >=12.0kPa (90mmHg), but blood pressure decrease.Invalid is that blood pressure is unchanged, other severity of symptoms.
Therapeutic Method:
The oral embodiment of the present invention 2 capsule three months, one time 3,2 times on the one; It within 30 days, is a course for the treatment of; After one course for the treatment of, can according to symptom improve situation by one time 3,1 medication on the one.
Primary hypertension patient totally 84 examples of Pass Test case standard, wherein man 58 example, female 26 example, mean age 42.3 native 8.2 one full year of life, secondary hypertension patient is totally 118 examples, wherein man 69 example, female 49 example, one full year of life mean age 53.8 ± 12.1, average 7.6 ± 3.1 years of medical history, therapeutic effect is as following table one.
Table one Chinese medicine hypertension therapeutic of the present invention clinical effectiveness
| Curative effect judging standard | Effective | Effectively | Invalid | Amount to |
| Constitutional number of cases | 59 | 20 | 5 | 84 |
| Percentage ratio % | 70.24 | 23.81 | 5.95 | 100 |
| Secondary cases number of cases | 98 | 14 | 6 | 118 |
| Percentage ratio % | 83.05 | 11.87 | 5.08 | 100 |
Seen by upper table, the present invention treats hypertensive Chinese medicine composition and reaches 94.05% to the treatment total effective rate of essential hypertension (effective add effectively), and obvious effective rate reaches 70.24%; Reach 94.92g% to the treatment total effective rate of secondary hypertension (effective add effectively), obvious effective rate reaches 83.05%.
Claims (1)
1. treat a hypertensive Chinese medicine composition, it is characterized in that being made up of the raw material of following weight portion:
Pericarpium Zanthoxyli 6-10 part, Spica Prunellae 8-24 part, Fructus Trichosanthis 6-10 part, Radix Ophiopogonis 2-5 part, Fructus Lycii 8-14 part, Radix Glycyrrhizae 6-10 part.
2. the hypertensive Chinese medicine composition for the treatment of as claimed in claim 1, is characterized in that being made up of the raw material of following weight portion:
6 parts, Pericarpium Zanthoxyli, Spica Prunellae 18 parts, Fructus Trichosanthis 8 parts, Radix Ophiopogonis 3 parts, Fructus Lycii 10 parts, 6 parts, Radix Glycyrrhizae.
3. the hypertensive Chinese medicine composition for the treatment of as described in as arbitrary in claim 1-2, is characterized in that: described Chinese medicine composition is peroral dosage form.
4. the hypertensive Chinese medicine composition for the treatment of as claimed in claim 3, is characterized in that: described peroral dosage form is capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310325756.9A CN103405574B (en) | 2013-07-31 | 2013-07-31 | Medicinal composition for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310325756.9A CN103405574B (en) | 2013-07-31 | 2013-07-31 | Medicinal composition for treating hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103405574A CN103405574A (en) | 2013-11-27 |
| CN103405574B true CN103405574B (en) | 2014-12-24 |
Family
ID=49598648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310325756.9A Active CN103405574B (en) | 2013-07-31 | 2013-07-31 | Medicinal composition for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405574B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013699B (en) * | 2014-06-17 | 2015-05-06 | 梁存福 | Pharmaceutical composition for treating hypertension caused by hyperactivity of liver-yang |
| CN113769023B (en) * | 2021-09-23 | 2023-09-05 | 江苏省中医院 | A Chinese medicinal composition for treating hypertension and its quality detection method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526345B (en) * | 2012-03-17 | 2013-07-10 | 李伟丽 | Chinese medicinal composition for treating hypertension |
-
2013
- 2013-07-31 CN CN201310325756.9A patent/CN103405574B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103405574A (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1723926A (en) | Traditional Chinese medicine liquor and preparation method thereof | |
| CN101797301B (en) | Medicine for preventing and curing middle and old aged constipation | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN105497620A (en) | Health-care traditional Chinese medicine preparation for weight reduction and body building | |
| CN102526345B (en) | Chinese medicinal composition for treating hypertension | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN101199796B (en) | External antidiarrhoeal medicament, preparing method and function thereof | |
| CN104888131A (en) | Traditional Chinese medicine composition for treatment of insomnia | |
| CN103405574B (en) | Medicinal composition for treating hypertension | |
| CN102973840A (en) | Chinese traditional medicine composite for curing acne | |
| CN103800689A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN101850071A (en) | Chinese medicament for treating chronic nephritis | |
| CN101664518A (en) | Moist bath lotion composition, preparation method and application in preparing pharmaceuticals and health products for treating YIN-blood deficiency fatigue syndrome or adiposity | |
| CN101491612A (en) | Medicine for treating mammary hyperplasia and early breast cancer | |
| CN105056170A (en) | Application of traditional Chinese medicine composition in preparing drug for treating acute gastritis | |
| CN112043757B (en) | Health-preserving coffee and traditional Chinese medicine composition | |
| CN111643557B (en) | Pharmaceutical composition for preventing and treating sequela of deep venous thrombosis of lower limbs and preparation method and application thereof | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN101884747B (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN101843707B (en) | Chinese medicament for treating chronic hepatitis | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN105232609A (en) | Traditional Chinese medicine combination treating functional dyspepsia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG GUIXIA Free format text: FORMER OWNER: TANG GUOPING Effective date: 20141128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Guixia Inventor before: Tang Guoping |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TANG GUOPING TO: WANG GUIXIA Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 276401 LINYI, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141128 Address after: 276401 Yishui City, Linyi province Yishui County town of new lane, No. 18 Applicant after: Wang Guixia Address before: Shuangyuehu road 276017 in Shandong Province, Linyi city Luozhuang District king Villa District No. 8 Building 1 unit 401 room Applicant before: Tang Guoping |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 225819 Jiangsu city of Yangzhou province Baoying County Flood Water Town Industrial Zone in Liuliqiao Patentee after: Wang Guixia Address before: 276401 Yishui City, Linyi province Yishui County town of new lane, No. 18 Patentee before: Wang Guixia |
|
| CP02 | Change in the address of a patent holder |
Address after: 276401 Yishui City, Linyi province Yishui County town of new lane, No. 18 Patentee after: Wang Guixia Address before: 225819 Jiangsu city of Yangzhou province Baoying County Flood Water Town Industrial Zone in Liuliqiao Patentee before: Wang Guixia |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171213 Address after: 226131 Haimen County, Jiangsu, Nantong Province town government compound Patentee after: NANTONG LEYUE INDUSTRIAL LTD. Address before: 276401 Yishui City, Linyi province Yishui County town of new lane, No. 18 Patentee before: Wang Guixia |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220401 Address after: 102627 No. 2, west of the first floor, building 12, Liyuan District B, Huangcun Town, Daxing District, Beijing Patentee after: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. Address before: 226131 Yuelai town government compound, Haimen City, Nantong City, Jiangsu Province Patentee before: NANTONG LEYUE INDUSTRIAL LTD. |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 212, Building 5, Bottom Business, Tongguan District 1, Majuqiao Town, Daxing District Economic and Technological Development Zone (Tongzhou), Beijing 102600 Patentee after: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. Address before: 102627 No. 2, west of the first floor, building 12, Liyuan District B, Huangcun Town, Daxing District, Beijing Patentee before: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. |